Using Hemoperfusion with HA380 Filter to Improve Heart and Liver Transplant Outcomes

Safety and Feasibility Study of Using Hemoperfusion with HA380 Filter to Improve Heart and Liver Transplant Outcomes: Phase I Clinical Trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220919055992N2

Enrollment

Registered

2023-06-18

Start date

2022-10-31

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Donors of organs and tissues. Donors of organs and tissues

Interventions

Intervention group: This group includes organ donors who will undergo hemoperfusion through the HA380 cartridge. First, sternotomy, complete separation of the aortic arch arteries and simultaneous lig

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: eligible for organ donation have consent and aware of donation

Exclusion criteria

Exclusion criteria: liver cirrhosis heart failure prior heart surgery

Design outcomes

Primary

Measure	Time frame
The cardiac ejection fraction. Timepoint: six months and one year after transplantation. Method of measurement: month.;Survival of heart recipient. Timepoint: six months and one year after transplantation. Method of measurement: percent.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact?Sam Zeraatian-Nejad Davani?

Iran University of Medical Sciences

samzeraatian@yahoo.com+98 21 6435 1401

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026